Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707826 | 0.87 | LMNA (0.39) | LMNASMN1; SMN2ALDH1A1L3MBTL1HTT | |
| SCHEMBL28211544 | 0.78 | KMT2A (0.38) | LMNAALDH1A1HTTTSHRALDH3A1 | |
| SCHEMBL14198846 | 0.78 | SMN1; SMN2 (0.57) | LMNASMN1; SMN2ALDH1A1L3MBTL1TDP1 | |
| SCHEMBL28311125 | 0.77 | ALDH1A1 (0.43) | LMNASMN1; SMN2ALDH1A1HTTTSHR | |
| SCHEMBL5310644 | 0.77 | TSHR (0.44) | LMNASMN1; SMN2ALDH1A1L3MBTL1HTT | |
| SCHEMBL28996978 | 0.76 | ENPP2 (0.46) | — | |
| Magnesium SCHEMBL30746780 | 0.74 | ENPP2 (0.45) | — | |
| Hydrochloric Acid SCHEMBL29163882 | 0.74 | ENPP2 (0.45) | — | |
| SCHEMBL9152061 | 0.74 | L3MBTL1 (0.46) | LMNASMN1; SMN2ALDH1A1L3MBTL1HTT | |
| SCHEMBL28060072 | 0.74 | MEN1 (0.56) | LMNASMN1; SMN2ALDH1A1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110036012-A | Pyrido [3,4-d] pyrimidine derivatives and its pharmaceutically acceptable salt | 帝人制药株式会社 | 2019-07-19 | — | — | CN | disclosed |
| US-6759428-B2 | SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS | ROCHE PALO ALTO LLC | 2004-07-06 | — | — | US | disclosed |
| US-20040077646-A1 | Indole nitriles | ROCHE PALO ALTO LLC | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077646-A1 | Indole nitriles | TPH1, IDO1, NAT1 | LMNA 2522/4885SMN1; SMN2 1862/4885ALDH1A1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.